The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes
Surgery for Obesity and Related Diseases · 2024-07 · 20 (7) · 652-659
DOI: 10.1016/j.soard.2024.01.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2024-07. Verfasst von Daniel Castellano-Castillo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Intercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Biomedical Research Institute of Mala…. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Bariatric Surgery, Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely tied to obesity. The degree ranges from steatosis (MASL) and steatohepatitis (MASH) to liver cirrhosis. PCSK9 controls cholesterol and lipid particle transport to the liver. PCSK9 might interfere with the pathophysiology of MASLD and bariatric surgery (BS) outcomes of patients with MASLD. OBJECTIVES: Evaluate the relationship between serum and hepatic PCSK9 levels with the degree of MASLD and the metabolic outcome of BS. SETTING: University Hospital, Spain. METHODS: A total of 110 patients with obesity undergoing BS were classified according to liver histology as controls, MAS, and MASH. PCSK9 levels in serum were measured before and 6 months after BS using enzyme-linked immunosorbent assay. PCSK9 protein and mRNA levels in liver tissue were analyzed by immunohistochemistry and reverse transcriptase-polymerase chain reaction, respectively. RESULTS: Hepatic PCSK9 protein levels were diminished in MASL and MASH compared with patients without MASLD and showed a strong negative association with MASLD severity scores. Liver PCSK9 mRNA was higher in MASH compared with controls and MASL and showed positive associations with MASLD severity scores. There were no differences in serum PCSK9 pre or postBS between the groups. Pre- and postsurgery serum PCSK9 positively correlated with cholesterol fold-changes and body mass index (BMI), cholesterol, and low-density lipoprotein -cholesterol fold-changes, respectively. PCSK9 fold-change positively correlated with BMI changes and was the sole variable explaining BMI fold changes in a regression model. CONCLUSIONS: PCSK9 mRNA and protein in the liver might be associated with the degree of MASLD. Serum PCSK9 may be associated with cholesterol and/or BMI fold changes. Serum changes of PCSK9 after BS could explain BMI loss outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intercenter Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, Biomedical Research Institute of Malaga (IBIMA)-CIMES/University of Malaga (UMA), Malaga, Spain. Electronic…
- Obesity, Diabetes, and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
- Obesity, Diabetes, and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain; Department of General and Digestive System Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
- Obesity, Diabetes, and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain; Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, Murcia, Spain.
- Experimental Pathology Platform, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
- Department of General and Digestive System Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Castellano-Castillo, D., Núñez-Sánchez, M. Á., Balaguer-Román, A., Martínez-Sánchez, M. A., Fernández-Ruiz, V. E., Ferrer-Gómez, M., Martínez, C. M., Frutos, M. D., Queipo-Ortuño, M. I., Cardona, F., & Ramos-Molina, B. (2024). The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes. Surgery for Obesity and Related Diseases, 20(7), 652-659. https://doi.org/10.1016/j.soard.2024.01.017
Vancouver
Castellano-Castillo D, Núñez-Sánchez MÁ, Balaguer-Román A, Martínez-Sánchez MA, Fernández-Ruiz VE, Ferrer-Gómez M, et al. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes. Surgery for Obesity and Related Diseases. 2024;20(7):652-659. doi:10.1016/j.soard.2024.01.017
BibTeX
@article{CastellanoCastillo2024,
author = {Castellano-Castillo, Daniel and Núñez-Sánchez, María Ángeles and Balaguer-Román, Andrés and Martínez-Sánchez, María Antonia and Fernández-Ruiz, Virginia Esperanza and Ferrer-Gómez, Mercedes and Martínez, Carlos Manuel and Frutos, María Dolores and Queipo-Ortuño, María Isabel and Cardona, Fernando and Ramos-Molina, Bruno},
title = {The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes},
journal = {Surgery for Obesity and Related Diseases},
year = {2024},
volume = {20},
number = {7},
pages = {652--659},
doi = {10.1016/j.soard.2024.01.017}
}
EUVIMED